One of the main characteristics of cancer is the rapid proliferation of transformed cells. Cancer therapies aim to kill such cells. Cancer clones surviving therapy can be resistant to the treatment, but they can also lose the ability to proliferate. The ability of single cells to proliferate can be monitored in vitro and can provide insights into the sensitivity of tumor cells to chemotherapeutics. The following chapter describes how clonogenic hematopoietic cell growth can be determined with the colony formation assay.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/978-1-0716-2788-4_2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Design, synthesis, and in vitro antitumor evaluation of novel benzimidazole acylhydrazone derivatives.
Mol Divers
January 2025
State Key Laboratory of Green Pesticide, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Center for R&D of Fine Chemicals of Guizhou University, Guiyang, Guizhou, 550025, People's Republic of China.
This study focuses on the design, synthesis, and evaluation of benzimidazole derivatives for their anti-tumor activity against A549 and PC-3 cells. Initial screening using the MTT assay identified compound 5m as the most potent inhibitor of A549 cells with an IC of 7.19 μM, which was superior to the positive agents 5-Fluorouracil and Gefitinib.
View Article and Find Full Text PDFMorusin Reverses Epithelial-Mesenchymal Transition in Gallbladder Cancer Cells by Regulating STAT3/HIF-1α Signaling.
Chem Biol Drug Des
January 2025
Department of Hepato-Biliary-Pancreatic Surgery, Shaoxing People's Hospital, Shaoxing, People's Republic of China.
Gallbladder cancer is the most prevalent malignancy of the biliary tract and has a dismal overall survival even in the present day. The development of new drugs holds promise for improving the prognosis of this lethal disease. The possible anti-neoplastic role of morusin was investigated both in vitro and in vivo.
View Article and Find Full Text PDFInteraction of STIL with FOXM1 regulates SF3A3 transcription in the hepatocellular carcinoma development.
Cell Div
January 2025
Second Department of General Surgery, the First Hospital of Qiqihar, No. 700, Pukui avenue, Long sha District, Qiqihar, Heilongjiang, 161000, P. R. China.
Background: Dysregulation of SF3A3 has been related to the development of many cancers. Here, we investigated the functional role of SF3A3 in hepatocellular carcinoma (HCC).
Methods: SF3A3 expression in HCC tissues and cell lines was examined using RT-qPCR.
SMAD2/3 signaling determines the colony architecture in a hydrozoan, Dynamena pumila.
Differentiation
January 2025
Laboratory of Morphogenesis Evolution, Koltzov Institute of Developmental Biology RAS, Vavilova st. 26, Moscow, 119334, Russia. Electronic address:
Most hydrozoan cnidarians form complex colonies that vary in size, shape, and branching patterns. However, little is known about the molecular genetic mechanisms responsible for the diversity of the hydrozoan body plans. The Nodal signaling pathway has previously been shown to be essential for setting up a new body axis in a budding Hydra.
View Article and Find Full Text PDFAnticancer effects of OSW-1 on colorectal cancer cells via the ROS/NLRP3/Caspase-1 pyroptosis signaling pathway.
Int Immunopharmacol
January 2025
Department of Clinical Laboratory Medicine, The First Affiliated Hospital of Dalian Medical University Dalian Liaoning PR China. Electronic address:
Pyroptosis, a form of programmed cell death, has recently emerged as a compelling molecular mechanism associated with the efficacy of chemotherapeutic drugs in tumor treatment. OSW-1, derived from the bulbs of Ornithogalum saundersiae Baker, exhibits a diverse range of pharmacological effects. However, its specific antitumor effects on colorectal cancer (CRC) and the mechanisms underlying these effects remain elusive.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!